-
India strangles final Maoist bastion as mining looms
-
AI-powered robots offer new hope to German factories
-
Indonesia orangutan forest cleared for 'carbon-neutral' packaging firm
-
PGA Tour mulls pathway back for golfers as LIV plots survival
-
One month phone-free: Young Americans try digital detox
-
Questions about Tesla spending binge ahead of earnings
-
Rome summons Russian ambassador over insults against Meloni
-
US tells Afghans to choose Taliban home or DR Congo: activist
-
John Ternus to lead Apple in the age of AI
-
SpaceX partners with AI startup Cursor, may buy it for $60 bn
-
Mexico pyramid shooter inspired by Columbine attack, pre-Hispanic sacrifices
-
Mexico pyramid shooter planned attack, fixated on US massacre
-
Mbappe on the mark as Real Madrid sink Alaves
-
Rosenior blasts Chelsea flops after 'unacceptable' Brighton defeat
-
Inter roar back to beat Como and reach Italian Cup final
-
Lens sweep past Toulouse to reach French Cup final
-
Brighton crush Chelsea to pile pressure on under-fire Rosenior
-
Strait of Hormuz blockade drives up costs at Panama Canal
-
Trump extends ceasefire, says giving Iran time to negotiate
-
Michelle Bachelet hopes the world is ready for a female UN chief
-
Nowitzki, Bird among eight inductees into FIBA Hall of Fame
-
Stocks fall, oil climbs amid uncertainty over US-Iran talks
-
Iran war means more orders for US defense giants
-
Mexico pyramid shooting was planned attack, officials say
-
Trump's messaging on Iran grows increasingly erratic
-
Churchill Downs buys Preakness for $85 million
-
Unregulated AI like speeding with no steering wheel: AI godfather Hinton
-
Tourists return to Rio viewpoint after shootout scare
-
Maradona's daughter slams 'manipulation' of family by his doctors
-
Abhishek's 135 powers Hyderabad to third straight IPL win
-
Vance still in Washington as uncertainty mounts over US-Iran talks
-
No.1 Jeeno seeks first major win at LPGA Chevron event
-
New batch of World Cup tickets to go on sale
-
Material girl: Madonna offers reward for missing clothes
-
Maker of Argentina's first Oscar-winning film, Luis Puenzo, dies at 80:
-
Rape retrial hears Weinstein 'preyed' on aspiring US actress
-
Arrests, hangings, blackout: Iran cranks up wartime repression
-
Seixas relishes 'steep' challenge at Fleche Wallonne
-
US Fed chair nominee says will not be controlled by Trump
-
Singapore's Tang gets second term at UN's patent agency
-
Taiwan leader postpones Eswatini trip after overflight permits revoked
-
Lula warns will respond after US expels police attache
-
Trailblazer Karren Brady steps down from West Ham role
-
US Fed chair nominee says he will not be controlled by Trump
-
In Portugal, Lula urges return to multilateralism
-
Sinner wants to use Madrid to boost career Grand Slam chances
-
Renewables key to buffer fossil fuel energy shock: COP31 co-hosts
-
Chery wants to make small electric car in Europe
-
Donovan steps down as Bulls coach
-
US official says gas prices have peaked despite Iran war
enVVeno Medical Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
- Video webcast now available on-demand
IRVINE, CA / ACCESS Newswire / July 22, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that Rob Berman, CEO of enVVeno, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.

As part of the segment, Mr. Berman dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's products in development.
The on-demand video webcast is now available on virtualinvestorco.com as well as the Events page of the enVVeno website, envveno.com.
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insuffihttps://virtualinvestorco.com/summer-spotlight/cy (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
[email protected]
(908) 824-0775
MEDIA CONTACT:
Glenn Silver, FINN Partners
[email protected]
(973) 818-8198
SOURCE: enVVeno Medical Corporation
View the original press release on ACCESS Newswire
M.Thompson--AMWN